# Rubius Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rubius-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.rubiustx.com
- Total disclosed funding: $246M
- Latest round: Series C (Feb 23, 2018)
- Investors on record: 1

## About

Rubius Therapeutics, Inc. is a biotechnology company focused on developing innovative cellular medicines utilizing genetically engineered red blood cells for the treatment of cancer and autoimmune diseases.Rubius Therapeutics, Inc., founded in 2014, is based in Cambridge, US, and specializes in creating Red Cell Therapeutics™. The company has undergone no significant pivots in its strategy. It has raised a total amount of USD 200.00 mn through multiple funding rounds, including a Private Placement/Follow on of USD 200.00 mn on March 16, 2021. The company was founded by individuals with experience in the biotech sector, although specific previous ventures are not detailed. Rubius has completed 5 deals and was valued at USD 1.6 bn following its IPO in July 2017.Rubius Therapeutics, Inc. specializes in the development of Red Cell Therapeutics™, which are genetically engineered red blood cells aimed at treating critical medical needs, particularly cancer and autoimmune conditions. Their leading candidates, RTX-240 and RTX-224, focus on solid tumors and leverage advanced genetic engineering to enhance the immune response against cancer cells. The company targets healthcare providers and institutions primarily in North America and Europe, responding to the demand for innovative cellular therapies.In its most recent financial year of 2020, Rubius Therapeutics reported zero revenue while incurring an EBITDA loss of USD 172.50 mn in 2022. The company operates through strategic partnerships with biopharmaceutical firms to advance its Red Cell Therapeutics™, which are central to its revenue-generating efforts as they move through clinical trials towards commercialization.Rubius Therapeutics, Inc. plans to leverage its recent funding of USD 200.00 mn raised in March 2021 to support the development of its lead therapeutic candidates and expand into new markets, particularly within North America and Europe. The company aims to enhance its clinical pipeline and expects to launch its innovative therapies in a phased manner. Additionally, the proceeds from their previous IPO in July 2017, where they raised USD 241.11 mn, are anticipated to aid in ongoing research initiatives and the commercialization of its products.

## Funding rounds

- Series C, Feb 23, 2018, $101M — Flagship Pioneering
- Series B, Jun 21, 2017, $120M — Flagship Pioneering
- Series A, Dec 9, 2015, $25M — Flagship Pioneering

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B, Series C